Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

NCT04828486 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
BCLC Stage A Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Interventions

DRUG: Futibatinib
BIOLOGICAL: Pembrolizumab
OTHER: Quality-of-Life Assessment

Sponsor

Mayo Clinic